Company intelligence / Profile preview

Trius Therapeutics

San Diego, California, United Statespitchbook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Trius’s lead program was tedizolid phosphate (TR‑701), an oxazolidinone-class antibiotic targeting serious Gram-positive infections including MRSA. Tedizolid met all primary and secondary endpoints in two Phase III trials for acute bacterial skin and skin structure infections. The drug was submitted to the FDA after acquisition[2]. The company had partnered with Bayer for commercialization outside North America and the EU[2]. After acquisition by Cubist Pharmaceuticals in September 2013, further development/commercialization continued under Cubist and subsequently Merck & Co., which acquired Cubist in December 2014[1][2][4].

Therapeutic areas: Infectious Diseases
Modalities: small molecules (antibiotics)
Industry: Biotech

Drug pipeline

1 asset

tedizolid

Commercial

Indications: Acute bacterial skin and skin structure infections, MRSA infections

Partnerships

Bayer AG – partnership for commercialization rights outside North America/EU for tedizolid/TR‑701[2]

Beyond the preview

Go deeper on Trius Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trius Therapeutics.

Explore the full profile